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Marina Konopleva,2 Michael Andreeff,2 Jorge Cortes,2 DeborahMcCue,2 Hagop Kantarjian,2
Richard E. Champlin,1 Marcos de Lima1Patients with acute myeloid leukemia (AML) and internal tandem duplication of FMS-like tyrosine kinase
receptor-3 gene (FLT3-ITD) mutation have poor prognoses and are often treated with allogeneic hemato-
poietic stem cell transplantation (HSCT). Sorafenib, an inhibitor of multiple kinases including FLT3, has shown
promising activity in FLT3-ITD-positive AML. We treated 16 patients with FLT3-ITD-positive AML who re-
lapsed after HSCTwith sorafenib alone (n5 8) or in combination with cytotoxic chemotherapy (n5 8). The
number of circulating blasts decreased in 80% of cases, but none of the patients achieved complete remission
(CR); 3 achieved partial remission. Two patients were bridged to a second transplantation but both relapsed
within 3 months of the transplantation. Median overall survival (OS) was 83 days, with none surviving more
than a year. Sorafenib is not effective in the treatment of FLT3-ITD-positive AML relapsing after HSCT. Pre-
ventive strategies after HSCT may be more suitable for these high-risk patients.
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FMS-like tyrosine kinase receptor-3 (FLT3) is
a transmembrane protein important in proliferation and
survival of hematopoietic stem cells (HSC) upon activa-
tion [1]. Internal tandem duplication of the juxtamem-
brane domain of the FLT3 gene (FLT3-ITD) leads to
kinase activity and activation of downstream signaling
pathways including the MAPK pathway [2]. FLT3-
ITD has been reported in approximately a one-quarter
of patients with acute myeloid leukemia (AML) and is
associated with higher relapse rates and shorter survival
[3-5]. As the mutation portends an increased risk of
disease relapse following chemotherapy alone, allogeneic1Department of Stem Cell Transplantation, The
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quently proposed if a donor is identified. Although
a proportion of patients will be cured following this
approach, a significant number will suffer disease recur-
rence following the transplantation.
Sorafenib is an oral, small-molecule, multikinase
inhibitor that may restrain proliferation of leukemia
cells by inhibition of the MAPK pathway through
raf-1 induction of apoptosis through mcl-1 [6,7], in
addition to directly targeting mutant FLT3 [8]. It was
found to be active in patients with FLT3-ITD-positive
AML in phase I trials [9,10]. Sorafenib has also been
successfully used to treat relapsed FLT3-ITD-positive
AML following allogeneic HSCT [11-16]. Here, we
reviewed our experience with this drug in patients
with FLT3-ITD-positive AML who relapsed after
allogeneic HSCT.MATERIALS AND METHODS
We identified all patients who received sorafenib
for at least 7 days, either alone or with chemotherapy,
to treat FLT3-ITD-positive AML relapse after alloge-
neic HSCT in our institution. The retrospective chart
review protocol was approved by the institutional review
board (IRB). Demographic and transplant-related infor-
mation was collected, as well as relapse-specific data,
sorafenib dose, and duration of treatment. Treatment
Table 1. Patient Characteristics and Response to Therapy
(N 5 16)
Characteristics n (%)
Median age at diagnosis* 34 (20-63)
Antecedent hematologic history 4 (25%)




Sorafenib use before transplantation 6 (38%)
Complete remission at transplantation 3 (19%)
Donor type
Matched related 5 (31%)
Mismatched related 4 (25%)
Matched unrelated 5 (31%)
Unrelated cord blood 2 (13%)
Remission duration following transplantation
(months)*
3 (1-7)
Posttransplantation salvage therapy before
sorafenib
7 (44%)
Number of salvage regimens before sorafenib* 0 (0-5)
Sorafenib therapy
Alone 8 (50%)
In combination with chemotherapy 8 (50%)
Duration of sorafenib treatment in days (range)*
Alone 39 (10-100)
In combination with chemotherapy 7 (7-32)
WBC count before sorafenib (103/mL)* 22.6 (0.6-119)
Peripheral blast percentage before sorafenib* 65% (0%-80%)
Median percentage decrease in circulating
peripheral blasts (n 5 12)*
50% (0%-88%)
Bone marrow blast percentage before
sorafenib*
58.5% (12%-88%)
Median absolute decrease in bone marrow
blast percentage*
0% (0-46)
CR following sorafenib None
PR following sorafenib 3 (19%)
New or worsening GVHD following sorafenib 1 (6%)
Bridged to second transplantation 2 (13%)
Time from bridged second transplantation
to relapse (days)*
(53 and 106)
WBC indicates white blood cell; CR, complete remission; PR, partial
remission; GVHD, graft-versus-host disease.
*Median (range).
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ing Group criteria [17]. Overall survival (OS) was de-
fined as time from sorafenib initiation to death.
Actuarial survival curves were estimated according to
the Kaplan-Meier method, and the significance of
differences between the curves was estimated by the
log-rank test.RESULTS
Sixteen patients were treated (Table 1). Four
patients had a second transplantation before sorafenib
therapy, whereas 12 received sorafenib after the first
transplantation. Only 3 patients (19%) were in com-
plete remission (CR) at the time of the first transplan-
tation. The preparative regimen was of reduced
intensity (n 5 7) or myeloablative (n 5 9). Three pa-
tients received CD34-selected stem cells; hence, nei-
ther received graft-versus-host disease (GVHD)
prophylaxis nor developed GVHD. Of the remaining13 patients, 4 developed acute GVHD (aGVHD) of
the skin before disease relapse. All 13 were receiving
tacrolimus for prophylaxis or treatment of GVHD in
addition to mycophenolate mofetil (n5 3) or systemic
steroids (n 5 1) at the time of disease recurrence. The
median remission duration following transplantation
was 3 months (range: 1-7 months).
Sorafenib Treatment
Six patients (38%) had received sorafenib before
HSCT, either as part of the induction therapy or as
a salvage regimen. In 9 patients (56%), sorafenib with
or without chemotherapy was the first salvage therapy
following allogeneicHSCT.The drug was given either
alone or in combination with other cytotoxic therapy in
8 (50%) and 8 (50%) patients, respectively.
Sorafenib was used as a single agent orally twice
daily at 400 mg (n 5 6), or 600 mg (n 5 2), on a
3-week cycle, either 5 days on therapy and 2 days off
weekly, or 14 days on therapy and 7 days off therapy.
When combined with chemotherapy, sorafenib was
given as 400 mg daily (n 5 4) or 400 mg twice daily
(n 5 4). Combined therapy included cytarabine and
idarubicin (n 5 7), or azacitidine (n 5 1). Median du-
ration of single-agent sorafenib treatment was 39 days,
whereas median duration of sorafenib administration
with chemotherapy was 7 days. Of 8 patients who re-
ceived sorafenib alone, 4 developed grade $2 adverse
events that included a grade 2 increase in alanine ami-
notransferase, grade 3 fatigue, grade 3 diarrhea, and
grade 3 hyperbilirubinemia. None of the patients
experienced worsening or development of GVHD
after sorafenib treatment.
Response to Sorafenib
Nine patients had pre- and postsorafenib bone
marrow aspirations performed: 3 patients (19%)
achieved a partial remission. The responders included
2 patients who received sorafenib alone, and 1 patient
received sorafenib in combination with other chemo-
therapy agents. A bone marrow examination was not
performed in the remaining 7 patients because of dis-
ease progression (apparent from peripheral blast
counts), inadequate bone marrow samples, or patient
death. Peripheral blast data was available in the major-
ity (75%) of patients (unless pancytopenic).
The median decrease in bone marrow blast per-
centage was 0%, whereas median absolute reduction
in peripheral blood blast percentage was 50%. A re-
duction in the number of circulating blasts was evident
in 80% of the cases, similarly distributed in the single
agent versus combination therapy subgroups. Given
the low response rate, no dose or schedule appeared
superior. Of the 6 patients who had received sorafenib
before transplantation, 1 achieved a partial remission;
3 had at least a 50% reduction in peripheral blood
Figure 1. (A) OS of all patients treated with sorafenib. (B) OS of pa-
tients treated with single-agent sorafenib and those treated in combina-
tion with cytotoxic therapy (P 5 .45).
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(Figure 1). There was no difference in survival between
patients who received sorafenib alone or in combina-
tion with chemotherapy.
Two patients were ‘‘bridged’’ to a second trans-
plantation. One was a 22-year-old male transplanted
after failing induction chemotherapy who achieved
a brief remission after the first transplantation (2
months). Sorafenib and azacitidine induced a reduction
in marrow blasts, and a second transplantation was
performed, after which he relapsed in 3 months. The
second patient was a 61-year-old female who relapsed
14 days after the first transplantation. She then re-
ceived single-agent sorafenib, which led to a partial re-
mission, followed by a second allogeneic HSCT. Her
disease relapsed 1 month after this transplantation.DISCUSSION
Here, we reported a series of 16 FLT3-ITD-posi-
tive AML patients treated with sorafenib after failing
allogeneic HSCT. Our experience is in contrast to
that reported in the literature, which includes com-
plete molecular responses. Although this could beattributed to the particularly advanced disease in our
cases—only 3 patients underwent transplantation in
CR, and the majority relapsed within 100 days of
HSCT—it is striking that median survival here was
\3 months. Another potential reason for failing to re-
spond to sorafenib is the dose schedule used here. It is
possible that alternative schedules, such as continuous
dosing (single agent), or a different combination with
other agents may induce a sustainable inhibition of
FLT3, resulting in improved clinical response. In ad-
dition, Pratz and collaborators [18] recently showed
that the FLT3 ligand can interfere with the action of
kinase inhibitors, a mechanism that conceivably could
be operative here. Nevertheless, response to sorafenib
was dismal when compared with the CR rate of 44%—
previously reported from our institution—achieved in
AML/myelodysplastic syndrome (MDS) patients with
relapsed disease after HSCT who were treated with
chemotherapy [19].
It has been hypothesized that the antileukemia ef-
fect of FLT3 inhibitors could be improved by disrup-
tion of stroma–leukemia interaction through CXCR4
inhibition. FLT3-ITD appears to activate CXCR4
signaling. Zeng et al. [20] combined sorafenib with
the CXCR4 inhibitor AMD3465, demonstrating
complete blockage of prosurvival signaling pathways
in AML cell lines. Furthermore, AMD3465 enhanced
sorafenib-induced apoptosis in samples from
primary AML patients with FLT3 mutation. This
concept is under investigation in the transplantation-
and chemotherapy-only scenarios [21].
Others have postulated that sorafenib could increase
theprevalenceand severity ofGVHDafterTcell replete
HSCTbased on preliminary findings from amice study
[22]. Three patients were reported elsewhere to either
developor experienceworsening ofGVHDafter sorafe-
nib initiation [11,12,15]. However, none of our patients
experienced worsening GVHD with sorafenib, indi-
cating that larger number of patients will have to be
treated before conclusions can be drawn.
Leukemia relapse afterHSCTremains amajor cause
of treatment failure [23]. Current treatment options are
limited and include donor lymphocyte infusion, chemo-
therapy, and secondHSCT.Treatment choice is usually
based on institutional experience and disease character-
istics, but only a small minority of patients will benefit
from current salvage therapies. Longer remission dura-
tion after HSCT is probably the single most important
prognostic factor [24]. Prevention of relapse after
HSCT in patients with high-risk disease may be a better
strategy, ideally using FLT3 inhibitors for patients har-
boring this mutation. Modification of preparative regi-
mens with the inclusion of more effective antileukemic
agents [25], or the use of ‘‘sequential conditioning’’
with cytoreductive chemotherapy followed by reduced-
intensity conditioning (RIC) [26,27], may also reduce
relapse rates. Furthermore, preemptive treatment of
Biol Blood Marrow Transplant 17:1855-1877, 2011 1877Posttransplant Sorafenib in Relapsed FLT3-ITD AMLpatients with rising quantitative FLT3 polymerase chain
reaction levels, before hematologic relapse, is a possible
approach to be investigated. In a broader sense in AML,
we are currently investigating maintenance of remission
therapy with low-dose azacitidine [28]. Interestingly,
this drug was demonstrated by others to increase the ex-
pression of C/EBPd, a transcription factor that is fre-
quently suppressed in AML and exhibits growth
inhibitory properties in FLT3-ITD-positive AML cell
lines [29].
Our results would argue against using sorafenib as
described here to treat FLT3-ITD AML relapse after
allogeneic transplantation. Innovative approaches are
urgently needed to prevent and treat recurrence in this
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